Prevalence and spectrum of NKX2.5 mutations in patients with congenital atrial septal defect and atrioventricular block

YING-JIA XU¹, XING-BIAO QIU¹, FANG YUAN¹, HONG-YU SHI¹, LEI XU¹, XU-MIN HOU¹, XIN-KAI QU¹, XIU LIU², RI-TAI HUANG², SONG XUE², YI-QING YANG¹,² and RUO-GU LI¹

¹Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200030; ²Department of Cardiovascular Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127; ³Department of Cardiology, Cardiovascular Research Laboratory and Central Laboratory, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200030, P.R. China

Received January 6, 2016; Accepted December 21, 2016

DOI: 10.3892/mmr.2017.6249

Abstract. Congenital atrial septal defect (ASD) and progressive atrioventricular block (AVB) are the two most common phenotypes linked to NK2 homeobox 5 (NKX2.5) mutations in animals and humans. However, the prevalence and spectrum of NKX2.5 mutation in patients with ASD and AVB remain to be elucidated. In the present study, the coding exons and flanking introns of the NKX2.5 gene, which encodes a homeobox-containing transcription factor essential for development of the heart, were sequenced in a cohort of 62 unrelated patients with ASD and AVB, and subsequently in a mutation carrier's available family members. As controls, 300 unrelated, ethnically-matched healthy individuals were recruited, who were also genotyped for NKX2.5. The functional consequence of the mutant NKX2.5 was evaluated in contrast to its wild-type counterpart using a dual-luciferase reporter assay system. As a result, a novel heterozygous NKX2.5 mutation, p.Q181X, was identified in an index patient with ASD and AVB, with a prevalence of ~1.61%. Genetic analysis of the proband's pedigree revealed that the mutation co-segregated with ASD and AVB with complete penetrance. The nonsense mutation, which eliminated partial homeobox and the carboxyl terminus, was absent in the 600 control chromosomes. Functional evaluation showed that the NKX2.5 mutant had no transcriptional activity. Furthermore, the mutation disrupted the synergistic activation between NKX2.5 and GATA binding protein 4, another cardiac core transcription factor associated with ASD. The results of the present study expand the spectrum of NKX2.5 mutations linked to ASD and AVB, and indicated that NKX2.5 loss-of-function mutations are an uncommon cause of ASD and AVB in humans.

Introduction

The heart is the first organ to form during embryogenesis and a sufficient supply of oxygen and nutrients through the circulatory system is an essential prerequisite for embryonic growth and survival (1). The formation of a fully functional four-chambered heart from the early embryo involves a precisely coordinated process of cellular differentiation and integrated multi-cellular morphogenesis, and even slight perturbations of this biological process may lead to cardiac developmental abnormalities, which is highlighted by the fact that congenital heart disease (CHD) is the most common form of birth defect in humans, with an estimated prevalence of 1% in live births, and up to 10% of stillbirths (1-4). Congenital heart defects can be classified into two major categories of morphological malformations and functional anomalies, including cardiac arrhythmias and cardiomyopathies. Cardiac structural deformities are a leading contributor to infant morbidity and mortality rates, whereas defects in the development of cardiac conduction system confer a significantly increased risk of mortality throughout life (5). Although the genetic basis underpinning a number of these defects remains to be elucidated, the core cardiac transcription factors, which are expressed predominantly in the heart and mediate the expression of genes encoding cardiac structural proteins or regulatory proteins, are increasingly recognized as being important in the normal development of the heart (6). Mutations in certain genes encoding core cardiac transcription factors, including homeodomain-containing NK2 homeobox 5 (NKX2.5) and NKX2.6 (7-16), GATA-binding protein (GATA) 4, GATA5 and GATA6 (17-24), T-box protein (TBX) 5 and TBX20 (25-29), and a paired-like homeobox transcription factor, PITX2 (30-33), have emerged as major contributors to several types of congenital heart defects (2,5,6,34).
During the last decade, increasing evidence has demonstrated the essential role of the NKX2.5 transcription factor in embryonic cardiogenesis and postnatal cardiac adaptation, particularly in the development of the cardiac conduction system (1). In mice, NKX2.5 is expressed at high levels in the early heart progenitor cells of primary and secondary heart fields during embryonic morphogenesis, and continues to be expressed at a high level in the heart through adulthood (1). Of note, the expression of NKX2.5 is transiently elevated in specialized myocardial conduction cells during formation of the conduction system, indicating the importance of NKX2.5 in the development of the conduction system (1). In murine embryos completely null for Nkx2.5, embryonic death occurred at ~E9-10 due to arrested looping morphogenesis of the heart tube and growth retardation (35,36). In addition, in Nkx2.5-knockout mice, the number of cells in the cardiac conduction system were found to be directly associated with Nkx2.5 gene dosage, with homozygous mutant embryos lacking the primordium of the atrioventricular node (37). By contrast, mice homozygous for a ventricle-restricted knockout of Nkx2.5 showed no cardiovascular structural defects, but exhibited marked overgrowth of trabecular muscle and progressive complete heart block owing to hypoplastic atrioventricular node at birth (38). In humans, mutations in NKX2.5 have been associated with a wide spectrum of cardiovascular diseases, including congenital heart defects, such as atrial septal defect (ASD), ventricular septal defect, tetralogy of Fallot, bicuspid aortic valve, mitral valve deformations, subvalvular aortic stenosis, abnormal systemic venous return, hypoplasia of left heart and visceral situs inversus (2,5-9,39), dilated cardiomyopathy (10), arrhythmias, such as atrioventricular block (AVB), atrial fibrillation and ventricular tachycardia (10-12,34,40,42), and sudden cardiac death (12,43,44), of which ASD and AVB are the two most frequent phenotypes in patients carrying NKX2.5 mutations. Of note, in a murine knock-in model generated by knocking in a comparable NKKX2.5 missense mutation (p.R52G) previously identified in patients, pleiotropic cardiac anomalies, including ASD, ventricular septal defect, atrioventricular septal defect, Ebstein malformation of the tricuspid valve and ventricular noncompaction were observed, in addition to progressive AVB, and this was similar or more marked, compared with the cardiac anomalies found in humans harboring a heterozygous mutation of p.R52 G in NKX2.5 (45,46). These observational results suggest that NKX2.5 mutations are responsible for ASD and AVB, and evaluation of the prevalence and spectrum of NKX2.5 mutations in patients with congenital ASD and AVB is warranted. This study was sought to evaluate the prevalence and spectrum of NKX2.5 mutations in patients with congenital ASD and AVB.

Materials and methods

Study population. In the present study, 62 unrelated patients with congenital ASD and AVB were recruited from the Chinese Han population, who were admitted to Shanghai Chest Hospital from January 2011 to December 2013. The available family members of the index patient carrying an identified NKX2.5 mutation were also included. In addition, 300 unrelated healthy individuals, who were matched to the patients with ASD and AVB in ethnicity, gender and age, were recruited as controls. All study subjects underwent detailed clinical investigation, including familial, personal and medical histories, physical examination, routine laboratory tests in hospitals, transthoracic echocardiography, and standard 12-lead electrocardiogram. The clinical types of CHDs were determined using two-dimensional continuous wave Doppler and color Doppler techniques on transthoracic echocardiography. When there was a strong indication, transesophageal echocardiography, cardiac catheterization and angiography were performed to further clarify the cardiovascular anatomic malformations. The definition and classification of AVB, which are widely used clinically and are based on the extent (first, second or third degree) of a block and the site within the conduction system of a block, were described previously (47). In brief, first-degree AVB is referred to as prolongation of the PR interval, which is the time interval between onset of P-wave and onset of QRS complex, on the surface electrocardiogram. In second-degree AVB, certain atrial impulses are conducted to the ventricles; electrocardiographic manifestation is the association of certain QRS complexes with P waves. Second-degree AVB is further classified as type 1 or type 2. In type 1 block, progressive prolongation of the PR interval is observed prior to the occurrence of AVB (Wenckebach periodicity). In type 2, the block occurs abruptly without PR interval prolongation. In third-degree or complete AVB, no atrial impulses conduct to the ventricles; on the electrocardiogram, QRS complexes are independent of P waves. In certain cases, AVB is described as progressive if the electrocardiographic characterization of atrioventricular conduction worsens over time, for example when the block progresses from second to third degree (47). Patients with ASD who suffered from AVB following cardiac surgery or intervention for CHD, or had chromosomal abnormalities or syndromic cardiovascular anomalies, including Holt-Oram syndrome, Di George syndrome, Alagille syndrome and Axenfeld-Rieger syndrome, were excluded from the present study. The present study was performed in accordance with the principles outlined in the Declaration of Helsinki. The study protocol was reviewed and approved by the Ethics Committee of Shanghai Chest Hospital, Shanghai Jiao Tong University (Shanghai, China). Written informed consent was obtained from all adult participants and from parents of minors prior to the investigation.

Mutational analysis of NKX2.5. Peripheral venous blood samples (3 ml) were collected from the patients and control individuals. Genomic DNA was extracted from blood leukocytes (for most steps in the DNA purification procedure, centrifugation at a speed of 2,000 x g for 10 min at -4°C) using a Wizard Genomic DNA Purification kit (Promega, Madison, WI, USA), according to the manufacturer’s protocol. With the assistance of online Primer 3 software (http://bioinfo.ut.ee/primer3-0.4.0/), the primers used to amplify the coding exons and flanking introns of NKX2.5 by polymerase chain reaction (PCR) were designed as shown in Table 1. The referential genomic DNA sequence of NKX2.5 was derived from GenBank (https://www.ncbi.nlm.nih.gov/nuccore/NG_013340.1; accession no. NG_01,3340.1). PCR was performed with HotStar Taq DNA polymerase.
Table I. Primers for amplification of coding exons and flanking introns of NK2 homeobox 5.

<table>
<thead>
<tr>
<th>Exon</th>
<th>Forward primer (5'-3')</th>
<th>Reverse primer (5'-3')</th>
<th>Amplicon size (bp)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>CCATTGCTCGGCTACCATCCTG</td>
<td>TCTTGGGACGAAAGGACACC</td>
<td>543</td>
</tr>
<tr>
<td>2-a</td>
<td>CGTATGCAAGGCTACCATCCTT</td>
<td>ACGAAGTGGTTGTTGCGGC</td>
<td>599</td>
</tr>
<tr>
<td>2-b</td>
<td>GGCTGCTGAAAATCTACGTCC</td>
<td>GGTCATGGTGAGGACCCCTT</td>
<td>545</td>
</tr>
</tbody>
</table>

Alignment of multiple NKX2.5 proteins across species. The NKX2.5 protein sequences of humans were aligned with those of chimpanzee, monkey, dog, cattle, mouse, rat, fowl, zebrafish and frog using the online MUSCLE program (version, 3.6; http://www.ncbi.nlm.nih.gov/SNP) database, the 1000 Genomes Project (1000 G; http://www.1000genomes.org) database, the exome variant server (EVS; http://evs.gs.washington.edu/EVS) database and the human genome mutation (HGM; http://www.hgmd.org/) database were queried.

Expression plasmids and site-directed mutagenesis. The recombinant expression plasmids NKX2.5-pEFSA and GATA4-pSSRa, and the atrial natriuretic factor (ANF)-luciferase; ANF-luc) reporter plasmid, which contained 2,600 base pairs upstream of the transcriptional start site of the ANF gene and expresses Firefly luciferase, were provided by Dr Ichiro Shiojima at the Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine (Chiba, Japan). The identified mutation was introduced into the wild-type NKX2.5-pEFSA construct by site-directed mutagenesis using a complementary pair of primers (forward, 5'-AAACTACGTCCAGGTAGTGACAAGATCTGGT-3'; reverse, 5'-ACAGATTTGGACACTACGTGGAAGGTAGTTT-3') and the Quick Change II XL Site-Directed Mutagenesis kit (Stratagene; Agilent Technologies, Santa Clara, CA, USA), and confirmed by direct sequencing.

Cell culture, transfection and reporter gene assays. COS-7 cells, which were obtained from the cell bank at the Cardiovascular Research Laboratory of Shanghai Chest Hospital (Shanghai, China). The cells were cultured in Dulbecco's modified Eagle's medium (Gibco; Thermo Fisher Scientific, Inc.) supplemented with 10% fetal bovine serum (Gibco; Thermo Fisher Scientific, Inc.), 100 µg/ml penicillin and 100 µg/ml streptomycin under an atmosphere of 5% CO₂ at 37˚C. Transient transfections of cells at ~90% confluence were performed with Lipofectamine® 2000 reagent (Invitrogen; Thermo Fisher Scientific, Inc.) 24 h post-seeded at a cell density of about 1x10⁵ per well in 12-well plates. The internal control pGL4.75 plasmid (Promega Corp.), which expresses Renilla luciferase, was used in transfection assays to normalize transfection efficiency. The COS-7 cells were transfected with 0.4 µg wild-type or Q181X-mutant NKX2.5-pEFSA, in combination with 1.0 µg ANF-luc and 0.04 µg pGL4.75. For co-transfection experiments, 0.2 µg wild-type NKX2.5-pEFSA, 0.2 µg of Q181X-mutant NKX2.5-pEFSA, 1.0 µg of ANF-luc and 0.04 µg of pGL4.75 were used. For analysis of the synergistic transcriptional activation between NKX2.5 and GATA4, the COS-7 cells were transfected with the same quantity (0.2 µg) of each plasmid DNA (wild-type NKX2.5-pEFSA, GATA4-pSSRa, or Q181X-mutant NKX2.5-pEFSA) was used alone or in combination, in the presence of 1.0 µg ANF-luc and 0.04 µg pGL4.75. At 6 h post-transfection, the media was replaced with growth media and cells were maintained for 48 h. The transfected cells were washed twice with PBS and lysed using PLB buffer (Promega Corp.) for incubation at room temperature for 15 min. The Firefly and Renilla luciferase activities were measured using a Dual-Luciferase Reporter Assay system (Promega Corp.) according to the manufacturer’s protocol. The activity of the ANF promoter was determined as the fold activation of Firefly luciferase relative to Renilla luciferase. Three independent experiments were performed in triplicate for each cell transfection, and each value presented as the average of triplicate samples.

Statistical analysis. Statistical analyses were performed using SPSS version 18.0 (SPSS, Inc., Chicago, IL, USA). Continuous variables with normal distribution are expressed as mean and standard deviations. Categorical variables are expressed as numbers and percentages. Differences between two groups were compared using Student's unpaired t-test for continuous variables, and with the χ² test or Fisher's exact test.
Table II. Baseline clinical characteristics of the study population.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Patients (n=62)</th>
<th>Controls (n=300)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>31±15</td>
<td>32±7</td>
<td>0.4200</td>
</tr>
<tr>
<td>Male</td>
<td>39 (63)</td>
<td>190 (63)</td>
<td>0.9490</td>
</tr>
<tr>
<td>Family history of ASD and AVB</td>
<td>6 (10)</td>
<td>0 (0)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>History of syncope</td>
<td>15 (24)</td>
<td>0 (0)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Implanted cardiac pacemaker</td>
<td>18 (29)</td>
<td>0 (0)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Surgical or catheter-based ASD closure</td>
<td>41 (66)</td>
<td>0 (0)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Distribution of types of ASD</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ostium secundum ASD</td>
<td>51 (82)</td>
<td>0 (0)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Ostium primum ASD</td>
<td>9 (15)</td>
<td>0 (0)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Sinus venosus ASD</td>
<td>2 (3)</td>
<td>0 (0)</td>
<td>0.0289</td>
</tr>
<tr>
<td>Distribution of types of AVB</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>First-degree AVB</td>
<td>34 (55)</td>
<td>0 (0)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Second-degree AVB</td>
<td>12 (19)</td>
<td>0 (0)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Third-degree AVB</td>
<td>16 (26)</td>
<td>0 (0)</td>
<td>&lt;0.0001</td>
</tr>
</tbody>
</table>

ASD, atrial septal defect; AVB, atrioventricular block.

for categorical variables. P<0.05 (two-tailed) was considered to indicate a statistically significant difference.

Results

Clinical characteristics of the study population. In the present study, 62 unrelated patients with ASD and AVB were clinically evaluated for comparison with 300 unrelated healthy individuals. All patients had congenital ASD, confirmed by echocardiogram, and AVB, confirmed by electrocardiogram. There were six patients who also had a positive family history of ASD and AVB. Based on their medical histories, echocardiographic records and electrocardiographic results, the control individuals had neither CHD nor AVB. None of the control individuals had a family history of ASD or AVB. No statistical differences were found in ethnicity, gender or age between the patient and control groups. The baseline clinical characteristics of the study population are shown in Table II.

Identification of a novel NKX2.5 mutation. Sequence analysis of the NKX2.5 gene in 62 unrelated patients with ASD and AVB revealed a heterozygous substitution of thymine for cytosine in the first nucleotide of codon 181 (c.541C>T) in the index patient; this mutation was predicted to introduce a stop codon at amino acid 181, resulting in the production of a truncated protein with only the NH₂-terminal 180 amino acids remaining (p.Q181X). The DNA sequencing electropherograms showing the NKX2.5 mutation of c.541C>T and its control sequence are shown in Fig. 1A. A schematic diagram of the NKX2.5 protein showing the functionally important structural domains and the location of the mutation identified in the present study is shown in Fig. 1B. The nonsense mutation was not detected in the 300 control individuals or in the SNP, 1000 G, EVS and HGM databases. Genotyping NKX2.5 in the proband's available family members showed that the heterozygous mutation was present in all three affected family members and absent in all four unaffected family members. Genetic analysis of the proband's pedigree unveiled that the mutation co-segregated with ostium secundum ASD and progressive AVB, which were transmitted in an autosomal dominant pattern with complete penetrance. In addition, the proband's father had ventricular septal defect and atrial fibrillation, and succumbed to mortality at the age of 60 years. The proband's younger sister also had an incomplete right bundle branch block. All the living affected family members underwent catheter-based closure of ASD. The pedigree structure of the family is illustrated in Fig. 1C. The clinical features of the affected family members are shown in Table III.

Alignment of the NKX2.5 proteins from various species. Alignment of the human NKX2.5 protein with those of chimpanzee, monkey, dog, cattle, mouse, rat, fowl, zebrafish and frog showed that the altered amino acid, p.Q181, was completely conserved evolutionarily (Fig. 2).

Functional failure of NKX2.5 protein resulted from mutation. As shown in Fig. 3, the same quantity (0.4 µg) of wild-type and Q181X-mutant NKX2.5 transcriptionally activated the ANF promoter by ~12-fold and ~1-fold, respectively (wild-type, vs. mutant; t=15.0303, P=0.0001); whereas 0.2 µg of wild-type NKX2.5 with 0.2 µg Q181X-mutant NKX2.5 activated the ANF promoter by ~6-fold (0.4 µg of wild-type, vs. 0.2 µg mutant + 0.2 µg wild-type; t=6.5294, P=0.0028).

Disrupted synergistic activation between NKX2.5 and GATA4 by the mutation. As shown in Fig. 4, the same quantity (0.2 µg) of wild-type NKX2.5, GATA4 and Q181X-mutant NKX2.5 activated the ANF promoter by ~7-fold, ~2-fold and ~1-fold, respectively. In the presence
Table III. Clinical features and mutational status of NKX2.5 in affected family members.

<table>
<thead>
<tr>
<th>Individual</th>
<th>Gender</th>
<th>Age (years)</th>
<th>Cardiac structural defects</th>
<th>Cardiac arrhythmias</th>
<th>Q181X mutation</th>
</tr>
</thead>
<tbody>
<tr>
<td>I-1</td>
<td>M</td>
<td>60(^a)</td>
<td>ASD, VSD</td>
<td>III(^0) AVB, AF</td>
<td>NA</td>
</tr>
<tr>
<td>II-1</td>
<td>M</td>
<td>47</td>
<td>ASD</td>
<td>II(^0) AVB</td>
<td>+/-</td>
</tr>
<tr>
<td>II-6</td>
<td>F</td>
<td>41</td>
<td>ASD</td>
<td>II(^0) AVB, IRBBB</td>
<td>+/-</td>
</tr>
<tr>
<td>III-3</td>
<td>M</td>
<td>16</td>
<td>ASD</td>
<td>I(^0) AVB</td>
<td>+/-</td>
</tr>
</tbody>
</table>

\(^a\)Age patient succumbed to mortality. NKX2.5, NK2 homeobox 5; M, male; F, female; ASD, atrial septal defect; VSD, ventricular septal defect; AVB, atrioventricular block; I\(^0\), first-degree; II\(^0\), second-degree; III\(^0\), third-degree; AF, atrial fibrillation; IRBBB, incomplete right bundle branch block; +/-, heterozygous for Q181X mutation of NKX2.5; NA, not available.

Figure 1. A novel NKX2.5 mutation associated with familial ASD and AVB. (A) Sequence electropherograms show the heterozygous NKX2.5 mutation and its wild-type control. The arrow indicates the heterozygous nucleotides of C/T in the index patient with congenital ASD and AVB (mutant) or the homozygous nucleotides of C/C in the corresponding control subject (wild-type). The rectangle marks the nucleotides that comprise a codon of NKX2.5. (B) Schematic diagram illustrating the structural domains of NKX2.5. The mutation identified in patients with congenital ASD and AVB is shown above the truncated protein (mutant). (C) Pedigree structure of a family with congenial ASD and AVB, designated as family 1. Family members are identified as generations and numbers. Squares, male family members; circles, female family members; closed symbols, affected; open symbols, unaffected; symbol with a slash, deceased member; arrow, proband; +, carriers of the heterozygous mutation; -, non-carriers; NKX2.5, NK2 homeobox 5; NH2, amino-terminus; TN, tinman domain; HD, homeodomain; NK, nucleotide kinase domain; COOH, carboxyl-terminus; ASD, atrial septal defect; AVB, atrioventricular block.
of 0.2 µg wild-type GATA4, the same quantity (0.2 µg) of wild-type and Q181X-mutant NKX2.5 activated the ANF promoter by ~25-fold and ~2-fold, respectively (wild-type, vs. mutant; *P<0.01 and **P<0.001, compared with the same quantity of wild-type NKX2.5. ANF, atrial natriuretic factor; NKX2.5, NK2 homeobox 5.

Discussion

In the present study, a novel heterozygous NKX2.5 mutation of p.Q181X was identified in a family with congenital ASD and AVB. The nonsense mutation was absent in 600 control chromosomes from a control population matched for ethnicity, gender and age. The mutation was predicted to yield a truncated protein lacking multiple functionally important domains. Reporter gene assays demonstrated that the Q181X-mutant NKX2.5 protein showed loss of transcriptional activity. Furthermore, the Q181X mutation abrogated the synergistic activation between NKX2.5 and GATA4. Therefore, it is possible that genetically compromised NKX2.5 contributed to ASD and AVB in these mutation carriers.

In humans, the NKX2.5 gene is mapped to chromosome 5q34, coding for a protein of 324 amino acids, which is expressed at a high level in the human heart (11). The NKX2.5 protein contains an evolutionarily conserved homeodomain (HD), which is centrally located at amino acid positions 138-197, and functions to specifically recognize and bind to a consensus DNA motif, AAGTG, which is key in the transcriptional regulation of target genes, including ANF, brain natriuretic peptide and α-actin, either alone or in synergy with other transcription factors, including GATA4, TBX5, TBX20, heart and neural crest derivatives expressed 2 and paired-like...
homeodomain 2 (11,19,26,29,31,48,49). The NKX2.5 mutation of p.Q181X identified in the present study was located in the HD, and functional analyses revealed that the mutant protein showed loss of the ability to transcriptionally activate ANF, alone or together with GATA4. These findings supported NKX2.5 haploinsufficiency as an alternative pathogenic mechanism of ASD and AVB.

ASD is the second most common form of CHD with an estimated incidence of 1/1,500 live births worldwide, accounting for ~10% of all CHDs (43,44). Although small ASDs may close spontaneously during infancy or childhood, large ASDs or those remaining open into adulthood may cause a significant volume of blood being shunted from the left side of the heart to the right, leading to pneumonia, embolism, pulmonary vascular disease, congestive heart failure, atrial arrhythmias and sudden cardiac death (43). In addition, familial AVB has been observed as congenital or adult-onset type to occur together with ASD (43). Congenital complete AVB is associated with mortality rates ranging between 33 and 80% if heart rate is <50 beats per minute or it co-occurs with structural heart diseases; whereas the adult-onset type of familial AVB is of a progressive nature, and there are several reports of patients with normal electrocardiogram or a harmless first-degree AVB followed by sudden onset of second- and third-degree AVB or sudden cardiac death later in life (12,43,44). Therefore, identification of a novel NKX2.5 mutation underpinning ASD and AVB is of important clinical significance, particularly for genetic counseling in patients carrying the NKX2.5 mutation.

To date, >60 mutations in NKX2-5 have been reported to be associated with a wide range of cardiac phenotypes, of which ASD and AVB are the most commonly reported phenotypes, in ~68 and 66% of patients, respectively (43,44). In addition, >97% of familial cases present with clinically documented ASD and AVB (44). Of note, of all reported non-synonymous mutations, ~1/3 occur within the HD region (44). Functional deciphers of these NKX2.5 mutations have shown reduced transcriptional activity, alone or in synergy with its cooperative partners (44), similar to the present study. Additionally, the results of the present and previous studies (43,44) suggest that there appears to be a genotype-phenotype correlation of NKX2.5 mutations. All mutations causing truncations and all missense mutations in the HD region result in ASD with AVB.

In conclusion, the present study expands the mutational spectrum of NKX2.5 linked to ASD and AVB, providing additional evidence that the NKX2.5 loss-of-function mutation is an uncommon cause of ASD and AVB.

Acknowledgements

This study was supported in part by grants from the Key Program for Basic Research of Shanghai, China (grant no. 14JC1405500), the National Natural Science Fund of China (grant nos. 81270161, 81470372 and 81400244), the Natural Science Fund of Shanghai, China (grant nos. 13ZR1438400, 14ZR1438000 and 15ZR1438100) and the Major Development Program for Science and Technology of Shanghai Chest Hospital, Shanghai, China (grant nos. 2014YZDH10102 and 2014YZDH20500).

References


